For muscle-based temporomandibular pain, biofeedback reduces pain better than no treatment, and at least as well as an occlusal splint. Recent work places it mainly as a component of a cognitive-behavioural programme, and that combination ranks among the most effective treatments available. For awake bruxism, EMG biofeedback reduces clenching and sustained tooth contact, without a demonstrated benefit on pain.
Updated :
What the research shows
Biofeedback
Masticatory muscle EMG biofeedback (with thermal, EDA and respiratory), alone or combined with CBT — masticatory muscle pain
AAPB4EfficaciousNeuroLogic4Efficacioussame vs AAPB
Level 4 maintained. The AAPB's base is randomised trials in patients diagnosed by RDC/DC-TMD criteria: Mishra 2000 (n = 94, four arms; 52.2 % of the biofeedback group reached at least a 33 % reduction in characteristic pain intensity against 28.0 % of the no-treatment group), its one-year follow-up (Gardea 2001, biofeedback and combined arms still improved against no treatment), Gatchel 2006 (n = 101, early combined intervention superior at one year) and Shedden Mora 2013 (n = 58, biofeedback-based CBT against a dentist-delivered occlusal splint: both arms improved, gains maintained at six months). Yao 2023, a network meta-analysis of 153 randomised trials (n = 8,713), ranks CBT augmented with biofeedback or relaxation among the three most effective treatments for chronic TMD pain (risk difference 36 %, 95 % CI 33 to 39, for reaching the minimally important difference; moderate-to-high certainty), and two randomised trials from one group report large sustained gains (Vaddamanu 2026, Cranio, n = 100 against standard care, d = 1.15 on pain at three months; Vaddamanu 2026, Behaviour Research and Therapy, n = 120 against analgesics plus physiotherapy, mean difference 1.8 cm at eight weeks, 2.5 cm at six months). Level 5 is not reached: biofeedback is embedded in a CBT programme in every superiority trial, and González-González 2025 found no pain advantage.
EMG biofeedback — awake bruxism and parafunctional oral behaviours
Ages
Adult (18+)
Techniques
EMG biofeedback
AAPB0Not ratedNeuroLogic3Probably efficacious
Level 3. Bruxism itself was outside the AAPB rating's scope: it explicitly excluded studies using only an alarm-type signal rather than volitional control of the feedback signal, so the AAPB never rated this target. Volitional EMG biofeedback does reduce awake-bruxism behaviour. Vieira 2023 reviewed four randomised trials, all using masticatory muscle EMG activity as the main endpoint: auditory and visual biofeedback reduced excessive muscle activity within a few days, but three of the four were at high risk of bias and protocols were inconsistent. Foscaldo 2025 randomised 40 adults with TMD and awake bruxism confirmed by ecological momentary assessment to EMG biofeedback or botulinum toxin type A, single-blind: only the biofeedback arm reduced sustained tooth contact (p = 0.004) and global bruxism behaviour (p = 0.008), with no between-group difference and no improvement in pain or psychosocial scores through six months. Minakuchi 2022 (14 biofeedback articles) and Graham 2026 (9 studies, n = 165) both report benefit on specific bruxism parameters, with meta-analysis judged inappropriate. The behavioural endpoint is reached repeatedly; superiority over an active comparator on a clinical endpoint is not.
In short
Clinical reading
NeuroLogic Level 4 for masticatory muscle pain, the same as the AAPB level: Mishra's 2000 four-arm randomised trial (biofeedback alone produced the greatest end-of-intervention pain reduction), the Gardea 2001 one-year follow-up, Gatchel 2006 and Shedden Mora 2013, supported by the Yao 2023 network meta-analysis and two Vaddamanu 2026 trials. Awake bruxism is shown as a separate row that the AAPB never rated: Level 3, on repeated effects on bruxism behaviour without a demonstrated analgesic benefit.
Protocols
Surface EMG of masseter and temporalis (often with frontalis and trapezius, temperature, EDA and breathing), relaxation training and daytime tooth-contact awareness; 8-12 sessions, usually within a cognitive-behavioural programme, with home practice.
Limits
Applies to muscle-based TMD; structural joint disorders are not targeted. In every superiority trial biofeedback is delivered with CBT, so its own contribution is not isolated, and the Busse 2023 guideline is a conditional recommendation against biofeedback alone. González-González 2025 found no superiority over other interventions on pain. There is no assessor-blind trial with pain as the outcome, and no paediatric evidence: the indication is rated in adults only.
Study base
Three foundational randomised trials, including a one-year follow-up. 2022-2026 base: 10 publications indexed in the archive, all biofeedback (2 randomised trials, 2 network meta-analyses, 1 practice guideline, 5 systematic reviews), mostly on bruxism.
Brendan's perspective
Level 4 for masticatory muscle EMG biofeedback, unchanged from the AAPB, and the evidence is better than people expect: Mishra 2000 with the one-year follow-up in Gardea 2001, Gatchel 2006, and Yao 2023 ranking CBT augmented with biofeedback among the three most effective treatments for chronic TMD pain. Level 5 is out because in every superiority trial the biofeedback sits inside a CBT programme, and Busse 2023 recommends against it on its own. The bruxism row is new at 3, and I want the distinction kept sharp: Foscaldo 2025 beat botulinum toxin on sustained tooth contact and changed nothing on pain. Behaviour is not the same endpoint as suffering. In clinic: masseter and temporalis sEMG, daytime tooth-contact awareness, HRV; the jaw is also where clenching quietly contaminates the EEG, so I check it before reading anyone's beta. Tell the client the habit can change, and that pain relief is a separate promise.
Mishra et al. (2000) The relative efficacy of three cognitive-behavioral treatment approaches to temporomandibular disorders doi:10.1023/a:1005562126071
Gardea et al. (2001) Long-term efficacy of biobehavioral treatment of temporomandibular disorders doi:10.1023/a:1010682818427
Gatchel et al. (2006) Efficacy of an early intervention for patients with acute temporomandibular disorder-related pain: a one-year outcome study doi:10.14219/jada.archive.2006.0183
Shedden Mora et al. (2013) Biofeedback-based cognitive-behavioral treatment compared with occlusal splint for temporomandibular disorder: a randomized controlled trial doi:10.1097/AJP.0b013e3182850559
Yao et al. (2023) Management of chronic pain secondary to temporomandibular disorders: a systematic review and network meta-analysis of randomised trials doi:10.1136/bmj-2023-076226
Busse et al. (2023) Management of chronic pain associated with temporomandibular disorders: a clinical practice guideline doi:10.1136/bmj-2023-076227
Vaddamanu et al. (2026) Integrating multimodal behavioral therapy into temporomandibular disorders management: A randomized attention-controlled trial using DC/TMD axis II outcomes doi:10.1016/j.brat.2026.104964
González-González et al. (2025) Usefulness of biofeedback as a potentially educational treatment of temporomandibular disorders: a systematic review and network meta-analysis doi:10.1186/s12903-025-06789-3
Foscaldo et al. (2025) Comparing botulinum toxin and biofeedback therapies for awake bruxism: a randomized clinical trial doi:10.1186/s12903-025-07133-5
